Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.

Clinical and translational science - 1 Jan 2024

Turner Amy J, Haidar Cyrine E, Yang Wenjian, Boone Erin C, Offer Steven M, Empey Philip E, Haddad Andrew, Tahir Saba, Scharer Gunter, Broeckel Ulrich, Gaedigk Andrea

Abstract excerpt

The DPYD gene encodes dihydropyrimidine dehydrogenase, the rate-limiting enzyme for the metabolism of fluoropyrimidines 5-fluorouracil and capecitabine. Genetic variants in DPYD have been associated with altered enzyme activity, therefore accurate detection and interpretation is critical to predict metabolizer status for individualized fluoropyrimidine therapy. The most commonly observed deleterious variation is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Genotype

Share to Haplotypes

Share to Pharmacogenomic Testing

Source

Open in PubMed Open full text

Identifiers

PMID: 38129972
DOI: 10.1111/cts.13699
PMCID: PMC10777430

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.PMID 38129972Read ↗

DPYD Genotyping of Patients with Fluoropyrimidine Treatment: Results of Protocol Implementation and Outcomes of Patients Carrying Unusual DPYD Variants.Semantic proximity Read ↗

Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.Semantic proximity Read ↗

Opportunistic analysis of clinically actionable DPYD gene variants in a germline testing cohort in India.Semantic proximity Read ↗

Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.Semantic proximity Read ↗

DPYD genotype should be extended to rare variants: report on two cases of phenotype / genotype discrepancy.Semantic proximity Read ↗

Dihydropyrimidine dehydrogenase (DPYD) genetic testing and treatment with 5-fluoropyrimidines in cancer patients: prevalence of variants with decreased activity and chemotherapy outcomes.Semantic proximity Read ↗

Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.Semantic proximity Read ↗

Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD VariantsSemantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.Semantic proximity Read ↗

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with FluoropyrimidinesSemantic proximity Read ↗

Approach for Phased Sequence-Based Genotyping of the Critical Pharmacogene Dihydropyrimidine Dehydrogenase (DPYD).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.